Bruce A. Cohen

Northwestern University — United States

Immunology and Microbiology · Life Sciences

58h-index10.8kcitations146works10.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV Research and Treatment(41), Multiple Sclerosis Research Studies(38), HIV-related health complications and treatments(24), Polyomavirus and related diseases(19), HIV/AIDS Research and Interventions(18)

Publications143 total

Response to therapy in a cohort of patients with late-onset multiple sclerosis
Multiple Sclerosis Journal - Experimental Translational and Clinical·2025Open Access
Choosing initial MS therapy; personal, disease, and medication factors
Neurotherapeutics·2025· 2 citedOpen Access
How Do You Treat Plantar Fasciitis? How Do I Know if it is the First Branch of the Lateral Plantar Nerve (Baxter's Nerve)?
2024
Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical review
Annals of Clinical and Translational Neurology·2024· 40 citedOpen Access
Differential Diagnosis of Tumor-like Brain Lesions
Neurology Clinical Practice·2023· 12 citedOpen Access
Scheduled IVIG in Patients Treated with Alemtuzumab Reduces Autoimmune Adverse Reactions (4369)
Neurology·2021
Autologous Hematopoietic Stem Cell Transplant in Multiple Sclerosis
JAMA Neurology·2020· 62 cited
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Neurology·2020· 99 citedOpen Access
Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS
Journal of Neurology·2019· 4 citedOpen Access
Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis
Neurology·2019· 49 cited
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis
New England Journal of Medicine·2018· 270 citedOpen Access
Cladribine tablets added to IFN-β in active relapsing MS
Neurology Neuroimmunology & Neuroinflammation·2018· 60 citedOpen Access
Acute Exertional Upper-Extremity Rhabdomyolysis as a Result of a Single Training Event: Report of 3 Female Trainees.
PubMed·2018· 3 cited
Robot-guided ankle sensorimotor rehabilitation of patients with multiple sclerosis
Multiple Sclerosis and Related Disorders·2016· 35 cited
Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis
Contemporary Clinical Trials·2016· 66 citedOpen Access
Efficacy of Cladribine Tablets as Add-On to IFN-beta Therapy in Patients with Active Relapsing MS: Final Results from the Phase II ONWARD Study (P3.029)
Neurology·2016· 15 cited
Demonstration of equivalence of a generic glatiramer acetate (Glatopa™)
Journal of the Neurological Sciences·2015· 43 citedOpen Access
Oculomotor Deficiency after Cerebellar Cortical Lesions
Advances in oto-rhino-laryngology·2015· 4 cited
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
Neurology·2015· 65 citedOpen Access
Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions
Neurology·2014· 55 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Justin C. McArthur(17), Ola A. Selnes(13), Eric N. Miller(12), Giovanni Schifitto(9), James T. Becker(8), Leon G. Epstein(7), David M. Simpson(7), Richard K. Burt(7), Ned Sacktor(6), Karl Kieburtz(6), David B. Clifford(6), Constantin T. Yiannoutsos(6), Christina M. Marra(6), Michael McDermott(5), Karen Marder(5), S. Shriver(5), Ann Ragin(5), Ned Sacktor(4), Richard L. Skolasky(4), Harry Hollander(4)